M&A: Page 2

Baxter closes $350M acquisition of Sanofi's Seprafilm adhesion barrier

The company said it will immediately begin integrating the product, meant to reduce adhesion barriers in patients having abdominal or pelvic laparotomy procedures, into its advanced surgery business.

By Maria Rachal • UPDATED: Feb. 18, 2020 at 10:14 a.m.

Hologic unloads underperforming Cynosure medical aesthetics unit

"This divestiture was a long time coming and puts an end to a bad marriage," William Blair analyst Brian Weinstein said of Hologic's $1.6 billion deal in 2017. Now, the company expects $138 million in cash proceeds from its sale.

By Dana Elfin • UPDATED: Dec. 30, 2019 at 2:40 p.m.

Asian private equity group to buy Lumenis in $1B deal

The maker of minimally invasive devices used in aesthetic procedures competes with rivals like Candela Medical.

By Nick Paul Taylor • Nov. 20, 2019

Wright Medical growth slowed in run-up to Stryker deal

While Wright's Cartiva big toe treatment dragged on sales for a second straight quarter, Stryker expects the acquisition to bolster its broader extremities business, particularly in shoulder devices.

By Susan Kelly • Nov. 11, 2019

Exact Sciences closes Genomic Health deal, wins breakthrough tag for liver cancer blood test

The Cologuard maker said it intends to roll out the test for hepatocellular carcinoma in the second half of 2020.

By Maria Rachal • Nov. 08, 2019

Paclitaxel, foreign exchange among drags on BD's Q4

Still, executives are optimistic about integration of the 2017 acquisition of Bard, set to deliver $100 million in projected fiscal 2020 savings.

By David Lim • Nov. 05, 2019

Stryker goes to extrem(iti)es in $4B Wright Medical takeout

Worth $5.4 billion including debt, the deal dwarfs the K2M buyout and sent shares in extremities device maker Wright Medical soaring almost 30%.

By Maria Rachal • UPDATED: Nov. 4, 2019 at 11:03 a.m.

Exact Sciences Q3 revenue jumps 85% but Cologuard orders disappoint

Shares in the non-invasive colon cancer test manufacturer fell approximately 6% Wednesday. Exact plans to focus on increasing payer coverage of Cologuard and communicating its label expansion to doctors.

By David Lim • Oct. 30, 2019

UK regulator mulls blocking Illumina's $1.2B PacBio takeover

The watchdog said the union "would result in a significant reduction of competition," leading some analysts to predict the deal won't go through.

By Nick Paul Taylor • Oct. 25, 2019

Merged GTX medical seeks broader footprint in spinal cord stim market

GTX hopes to start clinical studies of an implantable spinal cord stimulation system during 2021, CEO Sjaak Decker told MedTech Dive.

By Dana Elfin • UPDATED: Oct. 22, 2019 at 4:02 p.m.

Abbott 'working through a handful of items' with FDA on FreeStyle Libre 2

Third-quarter revenue for the medtech came in at $8.08 billion, slightly below Wall Street expectations, but executives praised the growth of key products FreeStyle Libre, MitraClip and Alinity on its earnings call.

By David Lim • Oct. 16, 2019

Qiagen taps new CEO, restructures in 'clearly a bad day'

The company is also suspending next-generation sequencing-related instrument development as it pivots into a 15-year partnership with Illumina to develop in vitro diagnostic kits.

By David Lim • Oct. 08, 2019

Lantheus strikes deal to buy Progenics, sparking investor backlash

Velan Capital, a big shareholder in Progenics, accused management of selling at a "massive discount" and preventing investors from being heard.

By Nick Paul Taylor • Oct. 03, 2019

Medtechs keep shareholders happy, potentially at pipeline's expense: EY

The industry recorded its highest revenues ever within the last year, an analysis by the consultancy shows. Even as R&D spending grew 11%, those investments fell short of the proportion of cash returned to investors.

By Maria Rachal • Sept. 23, 2019

Baxter puts up $230M for noninvasive fluid monitor company

The medtech said it intends to incorporate Cheetah's technology, alongside its IV infusion pumps, IV fluids and medications, into a new integrated platform for patient monitoring now in development.

By Susan Kelly • Sept. 11, 2019

Stryker spends up to $500M to boost spine unit with imaging, robotics tech

The medtech said Monday it completed its buy of Mobius Imaging, which makes a mobile CT scanner, and Cardan Robotics, which develops radiology procedure technologies. 

By Maria Rachal • UPDATED: Oct. 21, 2019 at 9:34 a.m.

Vertex to buy preclinical biotech for $950M, searching a Type 1 diabetes cure

Semma Therapeutics' drug-device combination product aims to restore insulin secretion. The company has received funding from Medtronic.

By Andrew Dunn • Sept. 03, 2019

Elekta buys ProKnow to boost digital radiotherapy strategy

The Swedish company says ProKnow's capabilities are of particular value to its large customers, potentially helping give it an edge over rivals such as Varian Medical Systems.

By Nick Paul Taylor • Aug. 29, 2019

Boston Scientific closes acquisition of BTG

The medtech giant is betting that having the subsidiary will make it the "category leader" in interventional oncology tools and products.  

By Maria Rachal • UPDATED: Aug. 19, 2019 at 10:54 a.m.

Stryker acquires maker of device sterilization systems

The deal comes against a backdrop of heightened regulatory scrutiny of duodenoscope reprocessing after a spike in contamination cases and the closure of a Sterigenics​ plant in Illinois that sterilized a wide range of devices.

By Susan Kelly • Aug. 13, 2019

AFib device maker AtriCure to spend up to $300M in SentreHeart buyout

AtriCure announced Tuesday it completed its acquisition of SentreHeart.

By Maria Rachal • UPDATED: Aug. 14, 2019 at 9:28 a.m.

Siemens acquires Corindus Vascular Robotics for $1.1B

The now-completed takeover gives Siemens Healthineers an FDA-cleared and CE-marked system for endovascular coronary and peripheral vascular interventions.

By David Lim • UPDATED: Oct. 29, 2019 at 9:59 a.m.

Hill-Rom picks up wearable ventilator maker in $130M deal

The medical equipment and systems company announced it's adding Breathe Technologies to its respiratory care business, part of a unit that contributed to Hill-Rom's 3% quarterly revenue growth reported Friday.

By Maria Rachal • Aug. 02, 2019

Exact Sciences to gain breast, prostate cancer tests in $2.8B deal

The Cologuard maker is adding Genomic Health's Oncotype DX tests to its ranks, which together target a market worth an estimated $20 billion.

By Maria Rachal • July 29, 2019

Healthcare the lone growth driver for 3M in Q2

The unit posted 5.8% sales growth, providing some relief for the beleaguered conglomerate, which expects its $6.7 billion buyout of wound care company Acelity to close in the fourth quarter.

By Nick Paul Taylor • July 26, 2019